Cidara Therapeutics' CD388 is aimed at providing universal protection with a single yearly dose for each flu season. See why ...

Ireland’s SynOx Therapeutics has completed a second-round financing, raising $75 million, as it prepares to take its drug for tenosynovial giant cell tumour (TGCT) into phase 3 trials.

Roche’s CD20xCD3 bispecific antibody Columvi has improved survival when used as a second-line therapy for diffuse large B-cell lymphoma (DLBCL) in a phase 3 trial, setting up regulatory filings ...

Moderna (MRNA) stock trades flat as the U.S. cancels a $766M contract granted for the company to develop a vaccine against ...

Systems, air interfaces, performance and availability objectives for FSS, BSS and MSS, including IP-based applications and satellite news gathering ...